Medicinal cannabis in oncology practice: Still a bridge too far?

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 2886-2891

  De Jong, Floris A ^a   Engels, Frederike K ^a   Mathijssen, Ron H J ^a   Van Zuylen, Lia ^a   Verweij, Jaap ^a   Peters, Remco P H ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATROPINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABINOL; CANNABIS; COCAINE; DOCETAXEL; DRONABINOL; IMATINIB; IRINOTECAN; MEGESTROL; MUSCLE RELAXANT AGENT; OPIATE; PENTOBARBITAL; PROCHLORPERAZINE; SILDENAFIL; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; CANNABINOID; PLANT MEDICINAL PRODUCT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD PRESSURE; CANCER; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COORDINATION; DEPRESSION; DROWSINESS; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DYSPHORIA; EUPHORIA; GILLES DE LA TOURETTE SYNDROME; HEART RATE; HUMAN; MEDICAL PRACTICE; MEMORY; MULTIPLE SCLEROSIS; MUSCLE RELAXATION; NEURALGIA; NONHUMAN; NOTE; PERCEPTION; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SIDE EFFECT; TREATMENT INDICATION; ARTICLE; CANNABIS SMOKING; DRUG INTERACTION; ETHNOLOGY; INFORMATION PROCESSING; NETHERLANDS; ONCOLOGY;

ANTIEMETICS; CANNABINOIDS; CANNABIS; DATA COLLECTION; DRUG INTERACTIONS; HUMANS; MARIJUANA SMOKING; MEDICAL ONCOLOGY; NETHERLANDS; PLANT PREPARATIONS;

EID: 19444382696     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.150     Document Type: Note

References (49)

1. Dutch Ministry of Health, Dutch Institute for Responsible Use of Medicine: Medicinal Cannabis: Information for medical doctors and pharmacists. The Hague, the Netherlands, Office of Medicinal Cannabis [in Dutch), 2003 http://www.cannabisbureau.nl/pdf/MedicinaleCannabis_Nov3.pdf
2. Grotenhermen F: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360, 2003
3. Marinol (Dronabinol) Capsules: Product prescribing information [package insert]. Marietta, GA, Solvay Pharmaceutical Inc, 2003
4. Hall W, Solowij N: Adverse effects of cannabis. Lancet 352:1611-1616, 1998
5. Walsh D, Nelson KA, Mahmoud FA: Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11:137-143, 2003
6. Tramer MR, Carroll D, Campbell FA, et al: Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 323:16-21, 2001
7. Lane M, Vogel CL, Ferguson J, et al: Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6:352-359, 1991
8. Darmani NA, Johnson JC: Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488:201-212, 2004
9. Roila F, Donati D, Tamberi S, et al: Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88-95, 2002
10. Bartlett N, Koczwara B: Control of nausea and vomiting after chemotherapy: What is the evidence? Intern Med J 32:401-407, 2002
11. Radbruch L, Nauck F: A review of side effects and complications with cannabinoid treatment [in German]. Schmerz 17:274-279, 2003
12. Ashton CH: Pharmacology and effects of cannabis: A brief review. Br J Psychiatry 178:101-106, 2001
13. Haney M, Ward AS, Comer SD, et al: Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 141:385-394, 1999
14. Beal JE, Olson R, Laubenstein L, et al: Oronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97, 1995
15. Timpone JG, Wright DJ, Li N, et al: The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome: The DATRI 004 Study Group-Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses 13:305-315, 1997
16. Jatoi A, Windschitl HE, Loprinzi CL, et al: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 20:567-573, 2002
17. Davis MP, Dreicer R, Walsh D, et al: Appetite and cancer-associated anorexia: A review. J Clin Oncol 22:1510-1517, 2004
18. Killestein J, Uitdehaag BM, Polman CH: Cannabinoids in multiple sclerosis: Do they have a therapeutic role? Drugs 64:1-11, 2004
19. Zajicek J, Fox P, Sanders H, et al: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362:1517-1526, 2003
20. Jochimsen PR, Lawton RL, VerSteeg K, et al: Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 24:223-227, 1978
21. Noyes R Jr, Brunk SF, Baram DA, et al: Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15:139-143, 1975
22. Campbell FA, Tramer MR, Carroll D, et al: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13-16, 2001
23. Cichewicz DL: Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317-1324, 2004
24. Notcutt W, Price M, Miller R, et al: Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ′N of 1′ studies. Anaesthesia 59:440-452, 2004
25. Hollister LE: Health aspects of cannabis: Revisited. Int J Neuropsychopharmacol 1:71-80, 1998
26. Bachs L, Morland H: Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 124:200-203, 2001
27. Gupta BD, Jani CB, Shah PH: Fatal 'Bhang' poisoning. Med Sci Law 41:349-352, 2001
28. Jones RT: Cardiovascular system effects of marijuana. J Clin Pharmacol 42:58S-63S, 2002 (suppl 11)
29. Benowitz NL, Jones RT: Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 18:287-297, 1975
30. Mittleman MA, Lewis RA, Maclure M, et al: Triggering myocardial infarction by marijuana. Circulation 103:2805-2809, 2001
31. Gable R: Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse 19:263-281, 1993
32. Roth MD, Marques-Magallanes JA, Yuan M, et al: Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24:339-344, 2001
33. Roth MD, Arora A, Barsky SH, et al: Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med 157:928-937, 1998
34. Barsky SH, Roth MD, Kleerup EC, et al: Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst 90:1198-1205, 1998
35. Sidney S, Quesenberry CP Jr, Friedman GD, et al: Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8:722-728, 1997
36. Zhang ZF, Morgenstern H, Spitz MR, et al: Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 8:1071-1078, 1999
37. Llewellyn CD, Linklater K, Bell J, et al: An analysis of risk factors for oral cancer in young people: A case-control study. Oral Oncol 40:304-313, 2004
38. Rosenblatt KA, Daling JR, Chen C, et al: Marijuana use and risk of oral squamous cell carcinoma. Cancer Res 64:4049-4054, 2004
39. Efird JT, Friedman GD, Sidney S, et al: The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: Cigarette smoking and other lifestyle behaviors. J Neurooncol 68:57-69, 2004
40. Guzman M: Cannabinoids: Potential anticancer agents. Nat Rev Cancer 3:745-755, 2003
41. Massi P, Vaccani A, Ceruti S, et al: Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308:838-845, 2004
42. Hart S, Fischer OM, Ullrich A: Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64:1943-1950, 2004
43. Benowitz NL, Jones RT: Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism: Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther 22:259-268, 1977
44. Jusko WJ, Schentag JJ, Clark JH, et al: Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther 24:405-410, 1978
45. McLeod AL, McKenna CJ, Northridge DB: Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin Cardiol 25:133-134, 2002
46. Van Grinsven J, Westerik H: Medicinal use of cannabis: A report [in Dutch]. Utrecht, the Netherlands, Duo Market Research, 2003
47. Hall W, Degenhardt L: Medical marijuana initiatives: Are they justified? How successful are they likely to be? CNS Drugs 17:689-697, 2003
48. Niesink R, Rigter S, Hoek J: THC concentrations in weed, nederweed and hashish in Dutch coffee shops (2003-2004) [in Dutch]. Utrecht, the Netherlands, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, 2004
49. Janse AFC, Breekveldt-Postma NS, Erkens JA, et al: Medicinal cannabis in the Netherlands [in Dutch]. Utrecht, the Netherlands, PHARMO Institute for Drug Outcomes Research, 2004